New data from the phase 1/2 CodeBreaK100 and KRYSTAL‐1 trials demonstrated that both sotorasib and adagrasib had promising anti‐tumor activity in KRAS G12C‐mutated PDAC. This evidence concerns the gene KRAS and neoplasm.